exposure (AUC0-inf) of pegfilgrastim after subcutaneous administration at 100 mcg/kg was <START:auc> 22.0 (± 13.1) mcg·hr/mL <END> in the 6 to11 years age group (n = 10), 29.3
mcg·hr/mL in the 6 to11 years age group (n = 10), <START:auc> 29.3 (± 23.2) mcg·hr/mL <END> in the 12 to 21 years age group (n = 13),
the 12 to 21 years age group (n = 13), and <START:auc> 47.9 (± 22.5) mcg·hr/mL <END> in the youngest age group (0 to5 years, n = 11).
± 4.9 tmax (hr) 2.1 ± 0.8 3.5 ± 2.4 AUC <START:auc> (ng&#x2022;h/mL) 194 ± 78 <END> 230 ± 67 Cmin (ng/mL)c 7.1 ± 3.5 7.6 ± 3.1
2.1 ± 0.8 3.5 ± 2.4 AUC (ng&#x2022;h/mL) 194 ± 78 <START:auc> 230 ± 67 <END> Cmin (ng/mL)c 7.1 ± 3.5 7.6 ± 3.1 CL/F (mL/h/kg) 173
The mean area under the plasma concentration-time curve (AUC) is about <START:auc> 25 µg·hr/mL <END> at this dose. Pegaptanib is metabolized by nucleases and is generally
7.1 31.4 ± 17.8 57.6 ± 21 83 ± 35.2 AUC0-24 <START:auc> (mcg&#x2022;hr/mL) 27 ± 14 <END> 60 ± 20 65 ± 33 197 ± 183 269 ±
57.6 ± 21 83 ± 35.2 AUC0-24 (mcg&#x2022;hr/mL) 27 ± 14 <START:auc> 60 ± 20 <END> 65 ± 33 197 ± 183 269 ± 96 555 ±
83 ± 35.2 AUC0-24 (mcg&#x2022;hr/mL) 27 ± 14 60 ± 20 <START:auc> 65 ± 33 <END> 197 ± 183 269 ± 96 555 ± 311 t½ (hr)
AUC0-24 (mcg&#x2022;hr/mL) 27 ± 14 60 ± 20 65 ± 33 <START:auc> 197 ± 183 <END> 269 ± 96 555 ± 311 t½ (hr) 10.7 ± 6.4
± 14 60 ± 20 65 ± 33 197 ± 183 <START:auc> 269 ± 96 <END> 555 ± 311 t½ (hr) 10.7 ± 6.4 7 ± 2.1
± 20 65 ± 33 197 ± 183 269 ± 96 <START:auc> 555 ± 311 <END> t½ (hr) 10.7 ± 6.4 7 ± 2.1 8.1 ± 2.3
fraction of injected activity (FIA) vs. time curve in blood was <START:auc> 39 hours <END> . Over 7 days, a median of 7.2% of the injected
megestrol acetate was 753 (±539) ng/mL . The mean AUC was <START:auc> 10476 (±7788) ng x hr/mL <END> . Median Tmax value was five hours . In another study,
days. Mean Cmax and AUC values were 490 (±238) ng/mL and <START:auc> 6779 (±3048) hr x ng/mL <END> , respectively. The median Tmax value was three hours . The
Docetaxel clearance was 17.9±8.75 L/h/m2 , corresponding to an AUC of <START:auc> 4.20±2.57 µg.h/mL <END> . In summary, the body surface area adjusted clearance of docetaxel
. The mean Cmax and AUC values were 8545 µg/dL and <START:auc> 31305 hr&#x2022;µg/dL <END> , respectively, which were 1.42- and 1.67-fold higher than dose adjusted
in male and female healthy subjects. The AUC was increased from <START:auc> 1295 to 1663 ng·h/mL <END> in subjects older than 62 years taking 180 mcg PEGASYS ,
2.25 mg/m2   Marqibo a  Variable  N  Mean  SE  Median  Range AUC' 13  <START:auc> 14566 <END>   1766  13680  7036­26074 (h&#x2022;ng/mL)  CL  12  345   100  302  148­783 (mL/h)
Variable  N  Mean  SE  Median  Range AUC' 13  14566   1766  13680  <START:auc> 7036­26074 (h&#x2022;ng/mL) <END>  CL  12  345   100  302  148­783 (mL/h)  Cmax  13  1220  
3.5 Elimination Half-Life (hours) 27.5 28.2 Cmax (µg/mL) 2.6 2.9 AUCss <START:auc> (µg/mL&#x2022;h) 29 <END> 36 In addition, the pharmacokinetics of amphotericin B , administered as
Half-Life (hours) 27.5 28.2 Cmax (µg/mL) 2.6 2.9 AUCss (µg/mL&#x2022;h) 29 <START:auc> 36 <END> In addition, the pharmacokinetics of amphotericin B , administered as amphotericin
Half-Life (minutes) 38 Elimination Half-Life (hours) 39 Cmax (µg/mL) 2.9 AUCss <START:auc> (µg/mL&#x2022;h) 36 <END> An analytical assay that is able to distinguish between amphotericin B
0.3 (n=10)b 0.4 ± 0.2 (n=5)Area Under Blood Concentration-Time Curve (AUC0-24h) <START:auc> (µg*h/mL) 14.0 ± 7 <END> (n=14)b,c 17.1 ± 5 (n=5) Clearance (mL/h*kg) 436.0 ± 188.5 (n=14)b,c
3 ( 0 . 3 - 2 . 0 ) AUC <START:auc> ( ng &#x2022; hr / mL ) 38 . 8 <END> 10 . 4 42 . 8 8 . 4 t 1
4 ) ( 28 . 9 ) AUC 0 - &#x221e; <START:auc> 41 . 0 <END> 124 . 9 131 . 6 185 . 9 207 .
28 . 9 ) AUC 0 - &#x221e; 41 . 0 <START:auc> 124 . 9 <END> 131 . 6 185 . 9 207 . 3 341 .
) AUC 0 - &#x221e; 41 . 0 124 . 9 <START:auc> 131 . 6 <END> 185 . 9 207 . 3 341 . 5 ( ng
- &#x221e; 41 . 0 124 . 9 131 . 6 <START:auc> 185 . 9 <END> 207 . 3 341 . 5 ( ng &#x2022; hr /
. 0 124 . 9 131 . 6 185 . 9 <START:auc> 207 . 3 <END> 341 . 5 ( ng &#x2022; hr / mL ) (
. 9 131 . 6 185 . 9 207 . 3 <START:auc> 341 . 5 <END> ( ng &#x2022; hr / mL ) ( 10 . 6
15-minute infusion to healthy volunteers the mean AUC0-&#x221e; of aprepitant was <START:auc> 31.7 (± 14.3) mcg&#x2022;hr/mL <END> and the mean maximal aprepitant concentration (Cmax) was 3.27 (± 1.16)
20-minute infusion to healthy volunteers, the mean AUC0-&#x221e; of aprepitant was <START:auc> 37.38 (± 14.75) mcg&#x2022;hr/mL <END> and the mean maximal aprepitant concentration (Cmax) was 4.15 (± 1.15)
AUC0-24hr) of 0.7 to 1.6 times the human exposure (AUC0-24hr = <START:auc> 19.6 mcg&#x2022;hr/mL <END> ) at the recommended dose of 125 mg /day . Treatment
of aprepitant up to 1000 mg/kg twice daily (plasma AUC0-24hr of <START:auc> 31.3 mcg&#x2022;hr/mL <END> , about 1.6 times the human exposure at the recommended dose)
at oral doses up to 25 mg/kg /day (plasma AUC0-24hr of <START:auc> 26.9 mcg&#x2022;hr/mL <END> , about 1.4 times the human exposure at the recommended dose)
half-life values following a 3.0 mg/kg dose were 22.8 mg/L , <START:auc> 170.9 mg&#x2022;hr/L <END> , and 2.5 hours , respectively. 8 Reference ID: 3006450 In
half-life values following a 1.5 mg/kg dose were 12.9 mg/L , <START:auc> 95.0 mg&#x2022;hr/L <END> , and 2.0 hours , respectively. The mean Cmax, AUC0-&#x221e; ,
. The AUC for Ferrlecit bound iron varied by dose from <START:auc> 17.5 mg-h/L <END> ( 62.5 mg ) to 35.6 mg-h/L ( 125 mg ).
varied by dose from 17.5 mg-h/L ( 62.5 mg ) to <START:auc> 35.6 mg-h/L <END> ( 125 mg ). Approximately 80% of drug bound iron was
ELESTRIN ( 1.04 mg /d Estradiol ) Mean AUC0-24 (pg&#x2022;hr/mL) 335.2 <START:auc> 940.2 <END> Cmax (pg/mL) 21.6 66.7 Cave (pg/mL) 15.4 39.2 Cmin (pg/mL) 9.4
1.7 g ELESTRIN ( 1.04 mg /d Estradiol ) Mean AUC0-24 <START:auc> (pg&#x2022;hr/mL) 335.2 <END> 940.2 Cmax (pg/mL) 21.6 66.7 Cave (pg/mL) 15.4 39.2 Cmin (pg/mL)
non-hypersensitive patients. The area under the plasma concentration-time curve (AUC) was <START:auc> 9.5 ± 4.0 International Units/mL/day <END> in the previously hypersensitive patients and 9.8 ± 6.0 International Units/mL/day
9.5 ± 4.0 International Units/mL/day in the previously hypersensitive patients and <START:auc> 9.8 ± 6.0 International Units/mL/day <END> in the non-hypersensitive patients. 8 Reference ID: 3493576 13 NONCLINICAL TOXICOLOGY
Volume of Distribution (L/m2) 2.83 ± 0.145 2.72 ± 0.120 AUC <START:auc> (µg/mL&#x2022;h) 277 ± 32.9 <END> 590 ± 58.7 First Phase (Î»1) Half-Life (h) 4.7 ± 1.1
2.83 ± 0.145 2.72 ± 0.120 AUC (µg/mL&#x2022;h) 277 ± 32.9 <START:auc> 590 ± 58.7 <END> First Phase (Î»1) Half-Life (h) 4.7 ± 1.1 5.2 ± 1.4
